Associated Papers
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models.
Herencia-Ropero A et al.
Genome Medicine, 2024
39187844 (PubMed )
Supplement: 13073_2024_1370_MOESM3_ESM.xlsx › SNV
Detection of dysregulated protein-association networks by high-throughput proteomics predicts cancer vulnerabilities.
Lapek JD et al.
Nature Biotechnology, 2017
28892078 (PubMed )
Supplement: NIHMS73743-supplement-Supplementary_tables.zip › Supplementary_Table_10_Proteins_with_Nonsense_Mutations_26_Breast_Cancer_Cell_Lines.xlsx › Sheet2
Select a paper to view details